All assets associated with the tag: astrazeneca
CARY – Biopharma AstraZeneca has picked SAS to help search for new drug candidates utilizing SAS’ data analytics suite and […]
Drugmaker AstraZeneca has been selling its coronavirus vaccine at not-for-profit prices during the pandemic, as part of a promise to roll out the vaccine at cost through the crisis.
Rebecca Robbins and Todd Gregory, New York Times
AstraZeneca has booked its first profit from sales of its COVID-19 vaccine. Here's the latest.
President Joe Biden plans on sharing millions more doses of COVID-19 vaccines with other countries. Biden has already committed to sharing 60 million doses of the AstraZeneca vaccine by July 4.
AstraZeneca's vaccine is key to ending the global economic slump caused by the coronavirus. But a series of missteps by the drugmaker and new concerns over blood clots risk undermining public confidence in the shot and delaying the recovery.
A top vaccines official at the European Medicines Agency said on Tuesday that AstraZeneca's vaccine was linked to blood clots in a small number of recipients, the first indication from a leading regulatory body that the clots may be a real, if extremely rare, side effect of the shot.
Benjamin Mueller, New York Times
After teaming up with Oxford University, AstraZeneca produced a safe and effective COVID-19 vaccine in just nine months, a huge achievement that will help end the pandemic. But a series of missteps along the way has led to scathing criticism from policymakers and health officials.
AstraZeneca reiterated Wednesday that its COVID-19 vaccine was very effective at preventing the disease, based on more recent data than was included when the company announced the interim results of its U.S. clinical trial on Monday.
Rebecca Robbins and Benjamin Mueller, New York Times
Duke infectious disease specialist Dr. Cameron Wolfe, who worked closely with researchers in an AstraZeneca COVID-19 vaccine trial, discusses the vaccine's efficacy.
AstraZeneca's COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the company announced Monday.
Seven other European nations have suspended its use as well over reports that some people have developed blood clots after being vaccinated.
The Anglo-Swedish drugmaker said that production of a vaccine able to effectively combat new COVID-19 variants could take at least six months.